Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. noratest

NORATEST SIGNED

NORATEST: An e-Health solution for a better Alzheimer's diagnosis and management

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NORATEST project word cloud

Explore the words cloud of the NORATEST project. It provides you a very rough idea of what is the project "NORATEST" about.

direct    alzheimer    profit    biomarkers    cagr    360k    2016    business    innovative    online    12    signatures    detection    health    charging    accounting    worth    solution    prototype    adaptable    sales    reference    healthy    suffering    medical    5m    detecting    total    detect    company    2026    diseases    privacy    pay    model    ad    discriminate    neurodegenerative    advantages    molecular    duplicating    analytics    2    people    2030    platform    combined    accurate    patients    alzohis    computer    fast    revenue    dementia    issue    smart    first    2024    54m    32m    80m    tests    data    markets    roi    efficient    diagnostic    annual    blood    competitive    worldwide    combination    stages    hire    anticipating    2050    diagnosis    speed    diagnoses    gt    scalable    motivated    coupled    market    detectable    lack    17    improvements    care    producing    employees    invasive    earn    ones    usa    affordable    algorithm    shows    ddiagnosis    5    noratest    accumulate    almost    countries    disease    projected    leaders    global    trl6    efficiency   

Project "NORATEST" data sheet

The following table provides information about the project.

Coordinator		 ALZOHIS 

Organization address
address: RUE DU FAUBOURG POISSONNIERE 28
city: PARIS
postcode: 91400
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALZOHIS FR (PARIS) coordinator 50˙000.00

Map

 Project objective

Alzheimer's disease (AD) is a major medical problem and is currently an issue of global general interest as the total number of people with dementia is projected to reach ~80M in 2030 and almost duplicating this number by 2050. The lack of an efficient and affordable solution in the AD's health care sector has motivated our company Alzohis to develop NORATEST, a very unique and innovative e-Health platform producing significant improvements, in terms of speed efficiency, in the detection of neurodegenerative diseases. By means of a novel combination of biomarkers “signatures” detectable in the blood with a state-of-the-art computer algorithm NORATEST can discriminate patients suffering AD from those healthy ones, as well as detecting other neurodegenerative diseases. Our prototype, currently at TRL6, is the first reliable non-invasive molecular diagnostic method able to detect the disease in the very early stages, offering several competitive and innovative advantages such as: Cost-effective novel technology, fast, accurate, early ddiagnosis, data privacy coupled to smart analytics, user-friendly and highly scalable and adaptable platform. Our business model is a pay-per-use combined model of charging per analysis and direct online sales. The global AD market shows great opportunities for us since it was worth €2.5 B in 2016 and is set to reach €12.6 B by 2026 (CAGR of 17.5%). Worldwide we expect a market growth in both established and in developing countries, anticipating >5M annual AD's diagnoses in the two main markets leaders based in Europe (2.5-3.5M diagnoses/year) and USA (1.5-2.5M diagnoses/year) by 2024. Our company goal is to become the reference for AD's diagnosis in Europe. We estimated that in 5 years (end of Phase 2 project), we will accumulate 360K diagnosis tests sales (revenue €54M) accounting for ~2% of the EU and USA market. We expect to hire 40 new technical and sales employees and earn ~€32M profit, with a ROI of 6.5.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NORATEST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NORATEST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

MIGRATECH 4.0 (2019)

The revolution in micro-granulation technology for eco-friendly, production efficient, superior ceramic tiles

Read More